Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 17;10:805402. doi: 10.3389/fcell.2022.805402

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Jianfeng, Yutao and Jianbin.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Expression of INMT in three clinical stages and normal prostate tissues of TCGA-PRAD (p = 1.6e−11), Tx classification according to TNM stage of prostate cancer (AJCC, 2017). (B) The expression of INMT in various lymph node metastasis groups and normal tissues of TCGA-PRAD (p = 2.4e−45). (C) The expression of INMT in various Gleason score groups of TCGA-PRAD (p < 0.001). (D) The expression of INMT in the high PSA and low PSA groups of TCGA-PRAD (p = 0.012). (E,F) The expression of INMT protein in 30 pairs of clinical samples of prostate cancer (T) and adjacent non-cancerous prostate tissues (N) (p < 0.001). (G) Using survival analysis, we found that the disease-free survival time in the INMT high-expression group was significantly longer than in the INMT low-expression group in TCGA-PRAD (p = 0.005, Hazard Ratio = 0.58). (H) Pan-cancer analysis of the TIMER database showing the expression level of INMT in cancer tissues.